ATE358673T1 - Nf-kb-inhibitoren - Google Patents
Nf-kb-inhibitorenInfo
- Publication number
- ATE358673T1 ATE358673T1 AT03731435T AT03731435T ATE358673T1 AT E358673 T1 ATE358673 T1 AT E358673T1 AT 03731435 T AT03731435 T AT 03731435T AT 03731435 T AT03731435 T AT 03731435T AT E358673 T1 ATE358673 T1 AT E358673T1
- Authority
- AT
- Austria
- Prior art keywords
- kappab
- inhibitors
- diseases
- activation
- aminothiophene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38655702P | 2002-06-06 | 2002-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE358673T1 true ATE358673T1 (de) | 2007-04-15 |
Family
ID=29736178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03731435T ATE358673T1 (de) | 2002-06-06 | 2003-05-29 | Nf-kb-inhibitoren |
Country Status (8)
Country | Link |
---|---|
US (1) | US7300952B2 (de) |
EP (1) | EP1532135B1 (de) |
JP (1) | JP2005532359A (de) |
AT (1) | ATE358673T1 (de) |
AU (1) | AU2003240935A1 (de) |
DE (1) | DE60312997T2 (de) |
ES (1) | ES2285125T3 (de) |
WO (1) | WO2003104219A1 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003270701B2 (en) | 2002-10-31 | 2009-11-12 | Amgen Inc. | Antiinflammation agents |
US7696244B2 (en) | 2003-05-16 | 2010-04-13 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
WO2005105809A1 (en) * | 2004-05-04 | 2005-11-10 | F. Hoffmann-La Roche Ag | Thienopyridines as ikk inhibitors |
CN1950378A (zh) * | 2004-05-04 | 2007-04-18 | 霍夫曼-拉罗奇有限公司 | 作为ikk抑制剂的噻吩并哒嗪类化合物 |
US7812018B2 (en) | 2006-02-16 | 2010-10-12 | Millennium Pharmaceuticals, Inc. | Alpha carbolines and uses thereof |
WO2008069102A1 (ja) * | 2006-12-06 | 2008-06-12 | Calpis Co., Ltd. | 炎症性腸疾患予防治療剤 |
KR101323448B1 (ko) | 2008-10-02 | 2013-11-27 | 아사히 가세이 파마 가부시키가이샤 | 8위 치환 이소퀴놀린 유도체 및 이의 용도 |
JP6124409B2 (ja) * | 2012-02-09 | 2017-05-10 | 国立大学法人 東京医科歯科大学 | ベンゾチオフェン化合物、該化合物を有効成分とするオルタナティブオートファジー誘導剤及び抗癌剤、並びに抗癌活性を有する化合物をスクリーニングするための方法 |
WO2016041972A1 (en) * | 2014-09-15 | 2016-03-24 | Ecole Polytechnique Federale De Lausanne (Epfl) | Benzothiophene, benzyloxybenzylidene and indoline derivatives useful for the treatment of tuberculosis |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4782080A (en) * | 1985-09-16 | 1988-11-01 | Merck & Co., Inc. | N-alkenyl-2-hydroxybenzo(b)thiophene-3-carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors |
US6545027B1 (en) | 1995-06-07 | 2003-04-08 | Eli Lilly And Company | Methods of modulating NF-kB transcription factor |
CA2287922A1 (en) * | 1997-04-30 | 1998-11-05 | Eli Lilly And Company | Intermediates and processes for preparing benzo[b]thiophenes |
EP1324759A4 (de) | 2000-10-12 | 2004-05-12 | Smithkline Beecham Corp | Nf--g(k)b inhibitoren |
-
2003
- 2003-05-29 JP JP2004511289A patent/JP2005532359A/ja not_active Withdrawn
- 2003-05-29 AU AU2003240935A patent/AU2003240935A1/en not_active Abandoned
- 2003-05-29 EP EP03731435A patent/EP1532135B1/de not_active Expired - Lifetime
- 2003-05-29 AT AT03731435T patent/ATE358673T1/de not_active IP Right Cessation
- 2003-05-29 ES ES03731435T patent/ES2285125T3/es not_active Expired - Lifetime
- 2003-05-29 US US10/517,111 patent/US7300952B2/en not_active Expired - Fee Related
- 2003-05-29 WO PCT/US2003/016876 patent/WO2003104219A1/en active IP Right Grant
- 2003-05-29 DE DE60312997T patent/DE60312997T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE60312997T2 (de) | 2007-12-13 |
EP1532135A1 (de) | 2005-05-25 |
AU2003240935A1 (en) | 2003-12-22 |
ES2285125T3 (es) | 2007-11-16 |
US7300952B2 (en) | 2007-11-27 |
US20060058371A1 (en) | 2006-03-16 |
DE60312997D1 (de) | 2007-05-16 |
WO2003104219A1 (en) | 2003-12-18 |
EP1532135A4 (de) | 2005-11-09 |
EP1532135B1 (de) | 2007-04-04 |
JP2005532359A (ja) | 2005-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE414697T1 (de) | Nf-kb-inhibitoren | |
NO20061197L (no) | Proteasominhibitorer og fremgangsmater for anvendelse av samme | |
ATE513550T1 (de) | Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung | |
SE0203752D0 (sv) | New compounds | |
HK1089153A1 (en) | Proteasome inhibitors and methods of using the same | |
MA28176A1 (fr) | Inhibiteurs de la forme mutante du kit | |
ATE396731T1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
IS7812A (is) | Afleiður 4-tetrazólýl-4-fenýlpiperidíns til þess að meðhöndla verk | |
NO20065148L (no) | Monocykliske heterocykler som kinase inhibitorer | |
ATE418336T1 (de) | Verwendung von i kappa b-kinase inhibitoren in der schmerztherapie | |
DE50306850D1 (de) | Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen | |
ATE358673T1 (de) | Nf-kb-inhibitoren | |
DE60322898D1 (de) | Verwendung von isoflavonen zur förderung des schlankheitseffekts | |
TW200508233A (en) | Chk-1 inhibitors | |
DE602004022035D1 (de) | Verwendung von pthalide derivativen zur behandlung | |
ATE534380T1 (de) | Glepp-1-hemmer bei der behandlung von autoimmun- und/oder entzündungskrankheiten | |
ATE443044T1 (de) | Tace inhibitoren | |
WO2003086309A3 (en) | NF-κB INHIBITORS | |
ATE376416T1 (de) | Verwendung von ambroxol zur behandlung von chronischen schmerzen | |
DE60220825D1 (de) | Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks | |
ATE438859T1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz | |
ATE548040T1 (de) | Verwendung von vasopeptidase-inhibitoren zur behandlung von nephropathie | |
NO20062138L (no) | Anvendelse av ifenprodil i behandling av smerte |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |